XBiotech Inc.

XBiotech develops experimental medicines called monoclonal antibodies, which are proteins designed to fight disease by targeting specific harmful substances in the body. The company is working on treatments for inflammatory diseases like arthritis, infectious diseases, and cancer. Many of their experimental drugs focus on blocking a protein called interleukin-1 alpha, which the company believes plays a role in inflammation, blood clots, muscle wasting, and tissue damage. XBiotech was founded in 2005 and is based in Austin, Texas.